UCB SA (UCBJF)
OTCMKTS · Delayed Price · Currency is USD
269.34
-1.54 (-0.57%)
At close: Nov 17, 2025
UCB SA Revenue
UCB SA had revenue of 3.49B EUR in the half year ending June 30, 2025, with 38.43% growth. This brings the company's revenue in the last twelve months to 6.85B, up 25.56% year-over-year. In the year 2024, UCB SA had annual revenue of 6.15B with 18.72% growth.
Revenue (ttm)
6.85B EUR
Revenue Growth
+25.56%
P/S Ratio
6.26
Revenue / Employee
730.22K EUR
Employees
9,378
Market Cap
50.37B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.15B | 970.00M | 18.72% |
| Dec 31, 2023 | 5.18B | -265.00M | -4.87% |
| Dec 31, 2022 | 5.45B | -330.00M | -5.71% |
| Dec 31, 2021 | 5.78B | 430.00M | 8.04% |
| Dec 31, 2020 | 5.35B | 434.00M | 8.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 122.89M |
| Mid-Atlantic Home Health Network | 27.00M |
| Silence Therapeutics | 25.83M |
| China New Energy Group Co. | 12.51M |
| Nuo Therapeutics | 2.61M |
UCB SA News
- 1 day ago - PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors - Seeking Alpha
- 10 days ago - Decoding United Community Banks Inc (UCB): A Strategic SWOT Insight - GuruFocus
- 13 days ago - Half Year 2025 Ucb SA Earnings Call Transcript - GuruFocus
- 14 days ago - U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d) - PRNewsWire
- 20 days ago - Insider Sell: Richard Bradshaw Sells Shares of United Community Banks Inc (UCB) - GuruFocus
- 26 days ago - United Community Banks, Inc. (UCB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 26 days ago - UCB Reports Strong Q3 Results with Significant Growth in Revenue and Loans - GuruFocus
- 26 days ago - United Community Banks Inc. Announces Rise In Q3 Bottom Line - Nasdaq